Skip to main content

Biofrontera announces preliminary revenue figures for the full year 2020

Written by Customer Service on . Posted in Public Companies.

Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) — Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the full year 2020.
Biofrontera Group’s preliminary unaudited revenue for the period January 1 to December 31, 2020 was in the range of EUR 30.3 million to EUR 30.6 million compared to EUR 31.3 million in 2019.Preliminary revenues from product sales in the US were around EUR 16.6 million, compared to EUR 23.3 million in 2019 (-29%). In Germany, revenues from product sales amounted to approximately EUR 5.2 million, compared to EUR 4.6 million in fiscal year 2019 (+13%). In the rest of Europe, the Company generated product sales of around EUR 2.1 million, compared to EUR 2.6 million in 2019 (-18%).Total sales in the fourth quarter amounted to approximately EUR 9.6 million, compared to EUR 12.2 million in the previous year. Effective January 1, 2021, a price increase of approximately 5% for Ameluz® in the US led to stockpiling by some physicians in December 2020, albeit to a lesser extent than in the previous year, which contributed to the strong sales performance in the last quarter of the year.The 2020 financial year was dominated by the economic and social impacts of the Corona pandemic. The decline in US sales in particular was due to the development of the crisis situation there. However, this was compensated by the positive sales development in Germany and the one-time payment of EUR 6 million from Maruho Co., Ltd. under the licensing agreement signed in April 2020.Biofrontera AG, Hemmelrather Weg 201, 51377 LeverkusenISIN: DE0006046113
WKN: 604611Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: ir@biofrontera.comForward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering.These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate” and “intend,” among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section “Risk Factors,” and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.